<SEC-DOCUMENT>0001437749-25-004126.txt : 20250218
<SEC-HEADER>0001437749-25-004126.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218081510
ACCESSION NUMBER:		0001437749-25-004126
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250217
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				900772347
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38244
		FILM NUMBER:		25632806

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
		BUSINESS PHONE:		512-537-7997

	MAIL ADDRESS:	
		STREET 1:		1601 TRINITY STREET, BLDG. B
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>gnpx20241220c_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:gnpx="http://www.gnpx.com/20250217"><head>
	<title>gnpx20241220c_8k.htm</title>

	<!-- Created by RDG Portal -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-354">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-355">0001595248</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="gnpx-20250217.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001595248</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-02-17</xbrli:startDate>
<xbrli:endDate>2025-02-17</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>UNITED STATES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Washington, D.C. 20549</b>&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160; &#160;</div>

<div style="background-color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;line-height:.15;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:center;"><b>FORM <ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-18"><b><b><b>8-K</b></b></b></ix:nonNumeric></b>&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160; &#160;&#160;</div>

<div style="background-color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;line-height:.15;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CURRENT REPORT</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>PURSUANT TO SECTION 13 OR 15(d)</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-33"><span style="text-decoration: underline;"><b>February 17, 2025</b></span></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">Date of report (Date of earliest event reported)</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt 7.2pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-39"><span style="text-decoration: underline;"><b>GENPREX, INC.</b></span></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>&#160;</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-51"><span style="text-decoration: underline;"><b>Delaware</b></span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:29.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-56"><span style="text-decoration: underline;"><b>001-38244</b></span></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-61"><span style="text-decoration: underline;"><b>90-0772347</b></span></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">incorporation or organization)</div>
			</td>
			<td style="vertical-align:top;width:29.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Commission File Number)</div>
			</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Identification Number)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">&#160;</td>
			<td style="vertical-align:top;width:29.9%;">&#160;</td>
			<td style="vertical-align:middle;width:35%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-82"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>3300 Bee Cave Road, #650-227</b></span></b></span></ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-87"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>Austin</b></span></b></span></ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressStateOrProvince" id="ixv-92"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>TX</b></span></b></span></b></span></ix:nonNumeric></b></span></div>
			</td>
			<td style="vertical-align:top;width:29.9%;">&#160;</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-102"><span style="text-decoration: underline;"><b>78746</b></span></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</div>
			</td>
			<td style="vertical-align:top;width:29.9%;">&#160;</td>
			<td style="vertical-align:middle;width:35%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">Registrant&#8217;s telephone number, including area code: <span style="text-decoration: underline;"><b>(<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-115"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>512</b></span></b></span></ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-120"><span style="text-decoration: underline;"><b><span style="text-decoration: underline;"><b>537-7997</b></span></b></span></ix:nonNumeric></b></span></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-365">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-366">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-367">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:5.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-368">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:94.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Securities registered pursuant to Section&#160;12(b) of the Act:</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:37.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Trading</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:44.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Name of each exchange on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:37.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" name="dei:Security12bTitle" id="ixv-369">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20258K" name="dei:TradingSymbol" id="ixv-370">GNPX</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1.3%;">&#160;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:44.7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The <ix:nonNumeric contextRef="d20258K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-371">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Emerging growth company&#160;<ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-372">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 7.2pt; text-align: left;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">On <span style="color:#000000;">February 17</span>, 2025&#160;(the &#8220;<b><i>Effective Date</i></b>&#8221;), Genprex, Inc. (&#8220;<b><i>Genprex</i></b>&#8221; or the &#8220;<b><i>Company</i></b>&#8221;) and the University of Pittsburgh &#8211; Of the Commonwealth System of Higher Education (&#8220;<b><i>UP</i></b>&#8221;) entered into an amended and restated Exclusive License Agreement (the &#8220;<b><i>New UP License Agreement</i></b>&#8221;), which updates and consolidates into a single agreement the Prior License Agreements (as defined below). Pursuant to the New UP License Agreement, UP grants to Genprex a worldwide, exclusive license for certain patents and related technology, collectively referred to as the &#8220;<b><i>Licensed Technology</i></b>,&#8221; and a worldwide, non-exclusive license to use certain related know-how. The Licensed Technology covered by the New UP License Agreement is based on the same general gene therapy approach as covered under the Prior License Agreements (less the previously-licensed macrophage technology), whereby an adeno-associated virus vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. More specifically, the Licensed Technology covered by the New UP License Agreement is related to a gene therapy for both Type 1 diabetes and Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors controlled by insulin, glucagon and MafB promoters. As of the Effective Date, the New UP License Agreement effectuates the termination of, and amends, restates, replaces and supersedes in their entirety, the prior license agreements between Genprex and UP which were effective as of February 10, 2020 (as amended August 17, 2022 and November 3, 2022), December 29, 2022 and July 14, 2023 (collectively, the &#8220;<b><i>Prior License Agreements</i></b>&#8221;), provided that Genprex&#8217;s prior license from UP dated November 22, 2022 which covered the macrophage technology is being terminated in its entirety and is not incorporated into or covered by the New UP License Agreement.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The New UP License Agreement authorizes Genprex (including any affiliate of Genprex that agrees in writing to be bound by the New UP License Agreement to the same extent as Genprex) to make, have made, use and sell the Licensed Technology and to practice under the patent rights in the field of diabetes therapy. Genprex may enter into sublicensing arrangements for the rights, privileges and licenses granted under the New UP License Agreement upon prior written approval of UP; however, sublicensees shall not have rights to sublicense. Genprex agrees to use its best efforts to bring the Licensed Technology to market as soon as practicable, consistent with sound and reasonable business practice and judgment, to continue active, diligent marketing efforts for the Licensed Technology throughout the term of the New UP License Agreement, and to achieve certain milestones within specified time periods. Genprex agrees to submit annual progress reports to UP and, beginning in the year of the first commercial sale of the Licensed Technology, quarterly reports of manufacturing, sales and sublicense activities to UP, including information as would allow the calculation of amounts owing to UP on account of such activities, as well as Genprex&#8217;s calculation of such amounts.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">UP has reserved the royalty-free, nonexclusive right to practice the patent rights and know-how and to use the Licensed Technology for non-commercial education and research purposes, and Genprex agreed to sell products and/or services resulting from Licensed Technology to UP and its affiliates upon request at the price and terms as are made available to Genprex&#8217;s most favored customer. The licenses granted to Genprex under the New UP License Agreement are subject to the rights of the U.S. government, which may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the patent rights throughout the world.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">As consideration for the New UP License Agreement, Genprex agreed to pay UP an initial license fee, annual maintenance fees, running low single digit percentage royalties, minimum annual royalties in a fixed cash amount, a low&#160;double digit percentage share of non-royalty sublicense income, and certain milestone payments up to an aggregate of approximately $4,825,000, as well as patent prosecution expenses incurred prior to and after the effective date of the New UP License Agreement.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The New UP License Agreement remains in effect until the later of 20 years after the first commercial sale of the Licensed Technology or the expiration of the last valid claim of the patents licensed under the New UP License Agreement. UP may terminate the agreement in the event of Genprex&#8217;s uncured default for thirty (30) days following notice thereof from UP, failure to achieve the specified milestones within the specified time period, or practice of the licensed patent rights or know-how outside the field of diabetes therapy, or if Genprex ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the relief of debtors. Genprex may terminate the New UP License Agreement upon six months prior written notice to UP and payment of all amounts accrued or due to UP through the effective date of termination.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The foregoing description of the material terms of the New UP License Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, reference to the New UP License Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"><b>Item 1.02&#160;Termination of a Material Definitive Agreement.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The information set forth in Item 1.01 above is incorporated herein by reference. As disclosed in Item 1.01 above, effective as of the Effective Date, the New UP License Agreement effectuates the termination of, and amends, restates, replaces and supersedes in their entirety, the Prior License Agreements, provided that pursuant to a notice of termination delivered by Genprex to UP on the Effective Date and becoming effective six months thereafter, Genprex&#8217;s prior license from UP dated November 22, 2022 which covered the macrophage technology is being terminated in its entirety and is not incorporated into or covered by the New UP License Agreement.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Item 7.01 Regulation FD Disclosure.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><i>Press Release</i></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">On February 18, 2025, Genprex issued a press release regarding certain updates on its diabetes gene therapy program, including the New UP License Agreement.&#160; The full text of the press release&#160;is attached to this Current Report on Form 8-K as Exhibit 99.1.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"><b>Item 8.01 Other Events.</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"><i>Formation of Wholly-Owned Subsidiary</i></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">In connection with the intended separation of its diabetes clinical development program, on February 18, 2025, Genprex announced that it has formed a wholly-owned subsidiary, Convergen Biotech, Inc., to implement this initial step of the reorganization and facilitate separation of the diabetes program.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><b>Item 9.01: Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">(d) Exhibits.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Exhibit</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Number</b></div>
			</td>
			<td style="vertical-align:bottom;width:4.8%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#160;</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:86.2%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#160;Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">10.1#</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_759848.htm" style="-sec-extract:exhibit;">Exclusive License Agreement, dated February 17, 2025.</a></td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">99.1</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;"><a href="ex_759849.htm" style="-sec-extract:exhibit;">Press Release, dated February 18, 2025.</a></td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8.9%;">&#160;</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8.9%; text-align: center;">104</td>
			<td style="vertical-align:middle;width:4.8%;">&#160;</td>
			<td style="vertical-align:middle;width:86.2%;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"># Certain portions of this exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and Genprex, Inc. agrees to furnish supplementally to the U.S. Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request. The portions of this exhibit that were omitted by means of marking such portions with asterisks because the identified portions are both (i) not material, and (ii) the type that registrant treats as private or confidential.</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.3pt;text-align:left;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.3pt; text-align: center;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto&#160;duly authorized.</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;border-bottom: 1px #000000;;width:33.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>GENPREX, INC.</b></div>
			</td>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#160;</td>
			<td style="vertical-align:top;width:3.5%;">&#160;</td>
			<td style="vertical-align:top;width:29.6%;">&#160;</td>
			<td style="vertical-align:top;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: February&#160;18, 2025</div>
			</td>
			<td style="vertical-align:top;width:3.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</div>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>/s/ Ryan Confer</i></div>
			</td>
			<td style="vertical-align:top;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;border-bottom: 1px #000000;;width:55.1%;">&#160;</td>
			<td style="vertical-align:top;width:3.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ryan Confer</div>
			</td>
			<td style="vertical-align:top;width:11.8%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 55.1%;">&#160;</td>
			<td style="vertical-align: top; width: 3.5%;">&#160;</td>
			<td style="vertical-align: top; width: 29.6%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">President, Chief Executive Officer, and Chief Financial Officer</div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer and Principal Financial Officer)</div>
			</td>
			<td style="vertical-align: top; width: 11.8%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_759848.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_759848.htm</title>
	<!-- Generated by ThunderDome Portal - 2/15/2025 6:52:10 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT 10.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>CERTAIN IDENTIFIED INFORMATION MARKED WITH</b>&nbsp;&#8220;<b>[***]</b>&#8221;<b> HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXCLUSIVE LICENSE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">This Exclusive License Agreement (&#8220;Agreement&#8221;) is made and entered into as of as of the date of the last signature to this Agreement (&#8220;Effective Date&#8221;), by and between the University of Pittsburgh &#8211; Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (&#8220;University&#8221;), and Genprex, Inc., a Delaware corporation, with its principal business at 3300 Bee Cave Road, Suite 650-227, Austin, Texas 78746 (&#8220;Licensee&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, University is the owner by assignment from the inventors of certain patent rights, entitled &#8220;Virally-mediated endogenous neogenesis of beta cells yields autoimmune-resistant beta cells,&#8221; as further defined in Section 1.10 below and more particularly identified in Exhibit A attached hereto (&#8220;Patent Rights&#8221;) developed by George Gittes, et al, of the University faculty, and of certain know-how as further defined in Section 1.4 below and more particularly identified in number 1 of Exhibit D, attached hereto (&#8220;Know-How&#8221;);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, University is the owner by assignment from the inventors of certain patent rights, entitled &#8220;Insulin promoter for gene therapy for type 2 diabetes mellitus&#8221; as further definedin Section 1.10 below and more particularly identified in Exhibit A attached hereto (&#8220;Patent Rights&#8221;) developed by George Gittes, et al, of the University faculty, and of certain know-how as further defined in Section 1.4 below and more particularly identified in number 2 of Exhibit D attached hereto (&#8220;Know-How&#8221;);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, University is the owner by assignment from the inventors of certain patent rights, entitled &#8220;MafB promoter for gene therapy for diabetes&#8221; as further defined in Section 1.10 below and more particularly identified in Exhibit A attached hereto (&#8220;Patent Rights&#8221;) developed by George Gittes of the University faculty, and of certain know-how as further defined in Section 1.4 below and more particularly identified in number 3 of Exhibit D attached hereto (&#8220;Know-How&#8221;);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, University desires to have the Patent Rights utilized in the public interest;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, Licensee has represented to University, to induce University to enter into this Agreement, that Licensee is experienced in the development, production, manufacture, marketing and sale of products and/or the use of similar products to the Licensed Technology and that Licensee shall commit itself to a thorough, vigorous and diligent program of exploiting the Patent Rights so that public utilization results therefrom; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, Licensee desires to obtain a license under the Patent Rights and Know-How upon the terms and conditions hereinafter set forth.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">WHEREAS, University and Licensee entered into License Agreements and related Amendments for the above assigned technologies, dated December 29<sup style="vertical-align:top;line-height:120%;">th</sup> 2022 (insulin promoter); July 14<sup style="vertical-align:top;line-height:120%;">th</sup> 2023 (MafB promoter); Feb 10<sup style="vertical-align:top;line-height:120%;">th</sup> 2020, August 17<sup style="vertical-align:top;line-height:120%;">th</sup> 2022, November 1<sup style="vertical-align:top;line-height:120%;">st</sup> 2022 (glucagon promoter) (together the Prior Agreements), and the Prior Agreements are hereby terminated and replaced in their entirety by this Agreement as of the Effective Date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto, intending to be legally bound, agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 1 </b>&#8211;<b> DEFINITIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">For purposes of this Agreement, the following words and phrases shall have the following meanings:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Affiliate</u></b>&#8221;&nbsp;shall mean, with respect to University, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by University. With respect to Licensee, &#8220;Affiliate&#8221;&nbsp;means any company or legal entity that directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Licensee but only for as long as such control exists. For this definition, &#8220;control&#8221;&nbsp;means the possession, directly or indirectly, of the power to direct or cause the direction of the affairs or management of an entity, whether through the ownership of voting securities, by contract or otherwise.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Field</u></b>&#8221;&nbsp;shall mean diabetes therapy.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Licensed Technology</u></b>&#8221;&nbsp;shall mean any product or part thereof or service which is:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Covered in whole or in part by an issued, unexpired or pending claim contained in the Patent Rights in the country in which any such product or part thereof is made, used or sold or in which any such service is used or sold; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Manufactured by using a process or is employed to practice a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any such process that is included in Licensed Technology is used or in which such product or part thereof or service is used or sold.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Manufactured by or otherwise makes use of Know-How.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Licensee</u></b>&#8221;&nbsp;shall mean Genprex, Inc. Licensee may extend the license granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by this Agreement to the same extent as Licensee. For the sake of clarity, any specific reference to &#8220;Licensee&#8221;&nbsp;in any provision of this Agreement shall include such Affiliate regardless of whether aspecific reference to an &#8220;Affiliate&#8221;&nbsp;is made in such provision.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Know-How</u></b>&#8221;&nbsp;means (a) the University information set forth on Exhibit D and existing on the Effective Date, (b) whether or not covered by a Valid Claim in Patent Rights, and (c) useful or necessary to make, have made, use or sell the Licensed Technology in the Field.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.6</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;FDA</u></b>&#8221;&nbsp;means the United States Food &amp; Drug Administration or its successor.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.7</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;MafB Patent Claim</u></b>&#8221;&nbsp;shall mean a issued patent claim reciting a composition comprising an adeno-associated virus vector comprising a MafB promoter operably linked to a nucleic acid sequence encoding Pdx1 and a nucleic acid sequence encoding MafA, and [***] or a claim of similar scope.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.8</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Net Sales</u></b>&#8221;&nbsp;shall mean Licensee&#8217;s and any sublicensee&#8217;s invoice price for products or services included in Licensed Technology and produced hereunder less the sum of the following:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Actual cost of freight charges or freight absorption, separately stated in such invoice;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Actual trade, quantity or cash discounts allowed, if any; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Sales taxes, tariff duties, use taxes, and other taxes, excluding income taxes, separately stated on each invoice; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Other amounts actually refunded, allowed or credited due to rejection, returns, or reperformance of services, but not exceeding the original invoiced amount.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Sales, transfers, or other dispositions of any Licensed Technology, at or below cost, for charitable, promotional (including samples), pre-clinical, clinical, or regulatory purposeswill be excluded from Net Sales.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.9</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Non-Commercial Education and Research Purposes</u></b>&#8221;&nbsp;shall mean shall mean use of Patent Rights and/or Know-How (including distribution of biological materials covered by the Patent Rights) in the Field for academic research or other not-for-profit scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the Patent Rights in the production or manufacture of products for sale or the performance of services for a fee.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.10</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Non-Royalty Sublicense Income</u></b>&#8221;&nbsp;shall mean execution fees, maintenance fees, milestone fees and all other non-royalty payments received by Licensee from its sublicensees pursuant to any sublicense granted pursuant to Section 2.3 hereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.11</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Patent Rights</u></b>&#8221;&nbsp;shall mean University intellectual property described below and assigned to University:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The United States (&#8220;<b><u>U.S.</u></b>&#8221;) and foreign patents and/or patent applications listed in Exhibit&nbsp;A;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any non-provisional patent applications that claim priority to any provisional patent application listed in Exhibit A;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any and all foreign patent applications, foreign patents or related foreign patent documents that claim priority to the patents and/or patent applications listed in Exhibit A;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any and all divisionals, continuations, reissues, re-examinations, renewals, substitutions, and extensions of the foregoing; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any and all patents issuing from the foregoing.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.12</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Territory</u></b>&#8221;&nbsp;shall mean Worldwide.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.13</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Pivotal Trial</u></b>&#8221;&nbsp;means a controlled Phase III clinical trial, as defined by the US FDA, of Licensed Technology that is prospectively designed to demonstrate statistically whether such Licensed Technology is effective and safe for use in a particular indication in a manner sufficient to obtain regulatory approval to market such product in the United States, European Union, or other foreign jurisdiction.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.14</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><u>&#8220;Valid Claim</u></b>&#8221;&nbsp;shall mean a claim of (i) an issued and unexpired patent which has not been declared invalid or unenforceable in a court of appropriate jurisdiction, withdrawn, abandoned, or revoked, or (ii) a patent application which has not been withdrawn, abandoned, rejected, or revoked and has not been pending for more than six (6) years from the filing date.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 2 - GRANT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, to the extent it may lawfully do so, the right and exclusive license in the Territory to make, have made, use and sell the Licensed Technology in the Field and to practice under the Patent Rights in the Field for the Term set forth in Article 10 below. Licensee shall not practice the Patent Rights outside of the Field. University reserves the royalty-free, nonexclusive right to practice the Patent Rights and the Know-How and to use the Licensed Technology for Non-Commercial Education and Research Purposes. University and any nonprofit or governmental institution also have the right to publish or have published any University information included in the Licensed Technology, Know-How or Patent Rights. This Agreement does not include transfer of any materials.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, to the extent it may lawfully do so, the right and nonexclusive license in the Territory to practice the Know-How in the Field for the Term, unless the Agreement is terminated earlier in accordance with Article 10.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The license granted hereby is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;&nbsp;200 <i>et seq.</i>&nbsp;&nbsp;Pursuant to this law, the U.S. government may have acquired a nonexclusive, nontransferable, paid-up license to practice or have practiced for or on behalf of the U.S. the inventions described in the Patent Rights throughout the world.&nbsp;&nbsp;Pursuant to 35 U.S.C. &#167;&nbsp;200 <i>et seq.</i>&nbsp;&nbsp;Licensed Technology<b>&nbsp;</b>produced for sale in the U.S. shall be substantially manufactured in the U.S. (unless a waiver under 35 U.S.C. &#167;&nbsp;204 is granted by the appropriate U.S. government agencies).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall have the right to enter into sublicensing arrangements for the rights, privileges and licenses granted hereunder upon prior written approval of each sublicensee by University, except that sublicensees shall not have rights to sublicense.&nbsp;&nbsp;Such sublicense agreements shall include a royalty rate upon sublicense Net Sales in an amount at least equal to the rate set forth in Section 4.l(c).&nbsp;&nbsp;In all such sublicensing agreements, Licensee shall impose on the sublicensee an obligation to not practice the Patent Rights or Know-How outside of the Field.&nbsp;&nbsp;Upon the termination of this Agreement and upon the request of any sublicensee, any sublicenses granted prior to either party&#8217;s receipt of any termination notice under this Agreement shall survive termination, provided that such sublicensee: (a) is not at such time in breach of this Agreement; and (b) agrees in writing to assume all of the Licensee&#8217;s applicable obligations under this Agreement through an assumption agreement or amended license Agreement, as appropriate.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee agrees that any sublicense granted by it shall provide that the obligations to University of Articles 2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this Agreement.&nbsp;&nbsp;Each sublicense granted by Licensee pursuant to this Agreement shall include an audit right by University of sublicensee of the same scope as provided in Section 5.2 with respect to Licensee.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.6</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee agrees to forward to University a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30) days after each such sublicense agreement has been executed by both parties thereto; provided however, such sublicense or amendment may be redacted with respect to the sublicensee&#8217;s scientific and technical information.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.7</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The license granted hereunder shall not be construed to confer any rights upon Licensee by implication, estoppel or otherwise as to any intellectual property not specifically set forth in Exhibit A or Exhibit D hereof..</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 3 </b>&#8211;<b> DUE DILIGENCE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall use its best efforts to bring the Licensed Technology to market as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts for the Licensed Technology throughout the Term of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition, Licensee shall adhere to each of the following milestones:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***]; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">f.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall notify University in writing of the achievement of each milestone within thirty (30) days upon the achievement of the respective milestone.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee&#8217;s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis any one of the milestones set forth in Section 3.2 hereof shall be grounds for University to terminate this Agreement and upon termination all rights and interest to the Licensed Technology, Know-How and Patent Rights shall revert to University.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 4 </b>&#8211;<b> LICENSE CONSIDERATION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In consideration of the rights, privileges and license granted by University hereunder, Licensee shall pay royalties and other monetary consideration as follows:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Initial license fee, nonrefundable and noncreditable against royalties, of [***] due immediately and payable within thirty (30) days from the Effective Date of this Agreement;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Annual maintenance fees, non-refundable, non-creditable, and not to be prorated against any other payment or royalties due, in the following amounts until the first Net Sale of a Licensed Technology occurs:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Running royalties in the following amounts shall become due immediately and shall become payable as set forth in Section 4.2:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***] of Net Sales of Licensed Technology covered by a Valid Claim of Patent Rights; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***] of Net Sales of Licensed Technology NOT covered by a Valid Claim of Patent Rights, but which uses or was manufactured using Know-How.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Beginning with the first Net Sales, a minimum annual royalty in the amount of [***] per calendar year, but only to the extent such minimum royalty is greater than the aggregate annual royalty computed in accordance with Section 4.1(c) above; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A share of Non-Royalty Sublicense Income of [***].</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">f.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Milestone payments as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">iii.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">iv.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">v.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[***];</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All payments pursuant to this Agreement shall be made by ACH or by wire transfer in U.S. Dollars without deduction or exchange, collection or other charges and remitted via ACH or wire transfer, to the bank set forth in Article 11.&nbsp;&nbsp;Annual maintenance fees pursuant to Section 4.1(b) hereof shall be paid on the anniversary of the Effective Date of the calendar year in which they are due.&nbsp;&nbsp;Royalty payments pursuant to Section 4.1(c) hereof shall be paid within thirty (30) days after each March&nbsp;31, June 30, September 30 and December 31.&nbsp;&nbsp;Minimum annual royalties pursuant to Section 4.1(d) shall be due December 31 and paid by January 30 following the calendar year in which they are due.&nbsp;&nbsp;Non-Royalty Sublicense Income payments pursuant to Section 4.1(e) hereof shall be paid within thirty (30) days after receipt of payment by Licensee from sublicense. Milestone payments pursuant to Article 4.1 (f) shall be paid within thirty (30) days of milestone event date.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Taxes imposed by any foreign governmental agency on any payment to be made to University by Licensee shall be paid by Licensee without deduction from any payment due to University hereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The balance of any payments pursuant to this Agreement, including those specified in Section 6.2, which are overdue shall bear interest, compounded monthly, calculated from the due date until payment is received at the rate of [***] per annum.&nbsp;&nbsp;Payment of such interest by Licensee shall not negate or waive the right of University to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with respect to Licensee&#8217;s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The balance of any payments pursuant to this Agreement, including those specified in Section 6.2, which are overdue shall bear interest, compounded monthly, calculated from the due date until payment is received at the rate of [***] per annum.&nbsp;&nbsp;Payment of such interest by Licensee shall not negate or waive the right of University to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with respect to Licensee&#8217;s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall sell products and/or services resulting from Licensed Technology to University and its Affiliates upon request at such price(s) and on such terms and conditions as such products and/or processes are made available to Licensee&#8217;s most favored customer.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 5 </b>&#8211;<b> REPORTS AND AUDIT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Within thirty (30) days after each March 31, June 30, September 30 and December 31 of each year during the term of this Agreement beginning in the year of the first commercial sale of Licensed Technology, Licensee shall deliver to University true, accurate and detailed reports of the following information in a form as illustrated in Exhibit B:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Number of Licensed Technology products manufactured and sold by Licensee and all sublicensees;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Total billings for all such products;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Accounting for all Licensed Technology services used or sold by Licensee and all sublicensees;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Deductions set forth in Section 1.5;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Total royalties due;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">f.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Name and addresses of sublicensees; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">g.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Total Non-Royalty Sublicense Income received during such calendar quarter and total amount of payment due pursuant to Section 4.1(e).</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall keep full, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable to University hereunder.&nbsp;&nbsp;Such books of account shall be kept at Licensee&#8217;s principal place of business.&nbsp;&nbsp;Such books of account shall be open at all reasonable times for [***] following the end of the calendar year to which they pertain, and for [***] after the expiration or termination of this Agreement, for inspection by University or its agents for the purpose of verifying Licensee&#8217;s royalty statement or compliance in other respects with this Agreement.&nbsp;&nbsp;The fees and expenses of University&#8217;s representatives shall be borne by University; however, if an error of more than [***] of the total payments due or owing for any year is discovered, then Licensee shall bear University&#8217;s fees and expenses.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">No later than sixty (60) days after December 31 of each calendar year during the term of this Agreement, Licensee shall provide to University a written annual progress report, as illustrated in Exhibit C, describing Licensee&#8217;s progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding twelve-month period ending December 31.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding the above, University shall have the right, on an annual basis during the term of this Agreement and for [***] after the expiration or termination of this Agreement, to inspect technical and other information from Licensee sufficient to evidence whether and to what extent Licensee is: (a) practicing the Patent Rights and/or other University property licensed hereunder; and (b) meeting its diligence obligations under Article 3, above.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall report to the University the date of the first commercial sale of a Licensed Technology within sixty (60) days of occurrence in each country.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 6 </b>&#8211;<b> PATENT PROSECUTION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">University has or shall apply for, seek prompt issuance of and maintain during the term of this Agreement the Patent Rights in the U.S. and in such foreign countries as may be designated by Licensee in a written notice to University within a reasonable time in advance of the required foreign filing dates. University will confer with Licensee to develop a strategy for the prosecution and maintenance of Patent Rights. Licensee shall have the opportunity to advise and cooperate with University in the prosecution, filing and maintenance of such patents, and to the extent practicable, all documents prepared by University&#8217;s counsel for submission to governmental patent offices will be provided to Licensee for review and comment prior to filing.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall notify University immediately if, at any time during the term of this Agreement, Licensee or any of its sublicensees does not qualify as a &#8220;small entity&#8221;&nbsp;as provided by the U.S. Patent and Trademark Office.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All fees and costs, including attorneys&#8217;&nbsp;fees, relating to the filing, prosecution, maintenance, and post grant proceedings relating to the Patent Rights shall be the responsibility of Licensee, whether incurred prior to or after the Effective Date.&nbsp;&nbsp;Fees and costs incurred after the Effective Date, or fees and costs incurred before the Effective Date which are not included in the pre-agreement expenses shall be paid by Licensee within thirty (30) days after receipt of University&#8217;s invoice therefor.&nbsp;&nbsp;Additionally, Licensee shall be liable to University for all of University&#8217;s out-of-pocket filing, prosecution, and maintenance costs (including all attorneys&#8217;&nbsp;fees and costs), for any and all patent prosecution and maintenance actions that will be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement from University to patent counsel relating to the Patent Rights.&nbsp;&nbsp;Payments pursuant to this Section 6.2 are not creditable against royalties or any other payment due to University under this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 7 </b>&#8211;<b> INFRINGEMENT ACTIONS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall inform University promptly in writing of any alleged infringement of the Patent Rights by a third party and of any available evidence thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">During the term of this Agreement, Licensee shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the Patent Rights in the Field and in the Territory if Licensee has notified University in writing of its intent to prosecute; provided, however, that such right to bring such an infringement action shall remain in effect only for so long as the license granted herein remains exclusive.&nbsp;&nbsp;In furtherance of such right, University hereby agrees that Licensee may include University as a party plaintiff in any such suit, without expense to University.&nbsp;&nbsp;The total cost of any such infringement action commenced or defended solely by Licensee shall be borne by Licensee and University shall receive a percentage of any recovery or damages for past infringement derived therefrom which is equal to the percentage royalty due University under Article 4.&nbsp;&nbsp;Licensee shall indemnify University against any order for costs that may be made against University in such proceedings.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If within six (6) months after having been notified of any alleged infringement, Licensee shall have been unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if Licensee shall notify University at any time prior thereto of its intention not to bring suit against any alleged infringer, then, and in those events only, University shall have the right, but shall not be obligated, to prosecute at its own expense any infringement of the Patent Rights, and University may, for such purposes, use the name of Licensee as party plaintiff.&nbsp;&nbsp;University shall bear all costs and expenses of any such suit.&nbsp;&nbsp;In any settlement or other conclusion, by litigation or otherwise, University shall keep any recovery or damages for past infringement derived therefrom.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In the event that a declaratory judgment action alleging invalidity or infringement of any of the Patent Rights shall be brought against University, Licensee, at its option, shall have the right, within thirty (30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In any infringement suit either party may institute to enforce the Patent Rights pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples, specimens, and other evidence upon request.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 8 </b>&#8211;<b> INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">8.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall at all times during the term of this Agreement and thereafter indemnify, defend and hold University, its trustees, officers, faculty members, employees and affiliates (&#8220;<b><u>Indemnified Parties</u></b>&#8221;) harmless against all claims and expenses, including legal expenses and reasonable attorneys&#8217;&nbsp;fees, arising out of the death of or injury to any person or persons or out of any damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from:&nbsp;&nbsp;(i) the production, manufacture, sale, use, lease, consumption or advertisement of the Licensed Technology, (ii) the practice by Licensee&nbsp;&nbsp;or sublicensee of the Patent Rights and Know-How; or (iii) arising from or relating to this License Agreement.&nbsp;&nbsp;Licensee shall provide this defense and indemnity whether or not any Indemnified Party, either jointly or severally, is named as a party defendant and whether or not any Indemnified Party is alleged to be negligent or otherwise responsible for any injuries to person or property.&nbsp;&nbsp;The obligation of Licensee to defend and indemnify as set forth herein shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">8.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall obtain and carry in full force and effect liability insurance which shall protect Licensee and University in regard to events covered by Section 8.1 above, as provided below:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Commercial General Liability</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Coverage: Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Limits: [***] Combined Single Limits for Bodily Injury and Property Damage</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Products Liability</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">i.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Coverage: Products Liability</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 11%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">ii.</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Limits: [***] upon first use of Licensed Technology in humans or first commercial sale, whichever is earlier</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The University of Pittsburgh is to be named as an additional insured with respect to insurance policies identified in Sections 8.2(a) and 8.2(b) above.&nbsp; Certificates of insurance evidencing the coverage required above shall be filed with University&#8217;s Innovation Institute, 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, PA&nbsp; 15260, within thirty (30) days from the Effective Date of this Agreement and on or before July 1 of each subsequent year during the Term of this Agreement.&nbsp; Such certificates shall provide that the insurer will give University not less than thirty (30) days advance written notice of any material changes in or cancellation of coverage.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">8.3</p>
			</td>
			<td style="vertical-align: top; width: 93%; text-align: justify;">UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY.&nbsp;&amp;NBSP;UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS&#8217; AND EXPERTS&#8217; FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER.</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 9 </b>&#8211;<b> ASSIGNMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">This Agreement is not assignable without the prior written consent of University and any attempt to do so shall be null and void; except that, Licensee may assign this Agreement without the prior written consent to a third party, who is not a restricted party under US export control laws, in connection with the sale of all or substantially all of the assets to which this Agreement relates or in connection with a merger, acquisition, reorganization, or similar transaction involving the Licensee. For any permitted assignment to be effective, the assignee shall assume all obligations of Licensee set forth in this Agreement in writing, and such assumption agreement is promptly delivered to University upon execution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 10 </b>&#8211;<b> TERM AND TERMINATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The term of this Agreement shall be from the Effective Date until the later of i) 20 years after first commercial sale of the Licensed Technology or ii) expiration of the last Valid Claim of the Patent Rights; unless terminated earlier pursuant to Section 10.2 and 10.3 below.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">University shall have the right to terminate this Agreement, upon written notice, if:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee defaults in the performance of any of the obligations herein contained and such default has not been cured within thirty (30) days after receiving written notice thereof from University;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">b.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The practice of the Patent Rights or Know-How by Licensee or sublicensee is outside of the Field; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 8%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">c.</p>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee may terminate this Agreement upon six (6) months prior written notice to University and upon payment of all amounts accrued or due to the University through the effective date of termination, including patent cost reimbursement pursuant to Section 6.2 hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Upon termination of this Agreement, neither party shall be released from any obligation that accrued prior to the effective date of such termination.&nbsp;&nbsp;Licensee and any sublicensee may, however, after the effective date of such termination, sell all Licensed Technology which Licensee produced prior to the effective date of such termination, provided that Licensee shall pay to University the royalties thereon as required by Article 4 hereof and submit the reports required by Article 5 hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The provisions of Articles 6-8, Sections 10.4 and 10,5, Article 11, and Sections 13.5 and 13.8 shall survive any expiration or earlier termination of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 11 </b>&#8211;<b> NOTICES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">11.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section 11.3.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">In the case of University:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Innovation Institute&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">University of Pittsburgh</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">1st Floor Gardner Steel Conference Center</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">130 Thackeray Avenue</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Pittsburgh, PA&nbsp; 15260</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">ATTN: Director</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">In the case of Licensee, per Exhibit D.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">11.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any payments to University by ACH or wire transfer shall be directed as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"><u>University of Pittsburgh ACH/Wire Instructions </u><u>&#8211;</u><u> Innovation Institute</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">BANK ACCOUNT NUMBER:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">BANK ACCOUNT NAME:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">BANK ADDRESS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">TYPE OF ACCOUNT:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">BANK:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">SWIFT CODE:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">ABA Routing:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [***]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">REF: Innovation Institute Invoice #</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">[***]&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">The Licensee shall be responsible for all applicable fees and costs relating to any ACH or wire transfer, to include translation fees, without any deduction of such fees from amounts due to the University pursuant to this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">11.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">All invoices to Licensee generated by University under this Agreement will be sent electronically, via e-mail, in PDF format, unless instructed otherwise by Licensee in writing.</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>ARTICLE 12 </b>&#8211;<b> AMENDMENT, MODIFICATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">This Agreement may not be amended or modified except by the execution of a written instrument signed by the Director of the University of Pittsburgh Innovation Institute, his successor, or other designated University employee having signatory authority, and Licensee&#8217;s Chief Executive Officer.&nbsp; In connection with any agreed upon amendment or modification of this Agreement pursuant to this Article 12, Licensee shall be required to pay an Amendment Fee.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ARTICLE 13 </b>&#8211;<b> MISCELLANEOUS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.1</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania.&nbsp;&nbsp;The forum for any action relating to this Agreement, including those brought against individuals such as University employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the U.S. District Court for the Western District of Pennsylvania</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.2</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.3</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their legal counsel and/or other advisors with respect to the Patent Rights, Licensed Technology, and the terms of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.4</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The parties agree that this Agreement constitutes an arm&#8217;s length business transaction and does not create a fiduciary relationship.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.5</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Except as provided herein, nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of the other party, neither party shall use any designation of the other party in any promotional activity associated with this Agreement or the Licensed Technology. Neither party shall issue any press release or make any public statement in regard to this Agreement without the prior written approval of the other party. Licensee may use the name of the University in routine business correspondence, or as needed in appropriate regulatory submissions and disclosures made under state and federal securities laws, and may state the fact that the University is the licensor of the licensed Patent Rights and Know-How without the prior express written consent of the University.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.6</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee agrees that with respect to the performance of this Agreement or the practice of the rights granted by the University hereunder, it shall comply with any and all applicable U.S. export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department&#8217;s Office of Foreign Asset Controls.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.7</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Each Party agrees that in connection with this Agreement that it will abide by applicable laws and regulations.&nbsp;&nbsp;No Party will offer, promise or give, directly or indirectly, anything of value to any government official, political party official, political candidate, or employee thereof or to any third party while knowing that such item of value or any portion thereof may be offered, promised, or given to a government official, political party official, political candidate, or employee thereof for the purpose of obtaining or retaining business.&nbsp;&nbsp;Each Party specifically agrees that in connection with this Agreement, it will take no action, or omit to take any action, which would cause another party to be in violation of the applicable laws of the U.S., including the U.S. Foreign Corrupt Practices Act and/or any local laws regarding bribery as well as any U.S. anti-boycott laws.&nbsp;&nbsp;In addition, the Parties represent and certify that neither the Parties nor their officers, board members nor agents involved in the performance of this Agreement have been convicted of crimes involving theft, fraud, bribery, corruption or moral turpitude and that each is not now listed by any government agency as being debarred, suspended or proposed for debarment or suspension.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.8</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If Licensee challenges the validity or enforceability of University&#8217;s Patent Rights or University&#8217;s ownership of the Patent Rights anywhere in the world, the Licensee shall continue to pay to University all royalties and other financial obligations required under this Agreement, to include patent costs and fees.&nbsp;&nbsp;If any such challenge is unsuccessful by Licensee, the royalty rates and any non-royalty sublicense income rate set forth in Article 4.1 above shall automatically double in value, to include all royalty minimums and floors; and Licensee shall reimburse the University for all fees and costs associated with defending such action, including but not limited to attorney&#8217;s fees and expert fees.&nbsp;&nbsp;The&nbsp;effective date of such increase in royalty rates shall be the date of the first court order or date of issuance of a re-examination certificate (or foreign equivalents thereof) declaring any claim of the Patent Rights as valid or enforceable.&nbsp;&nbsp;Within thirty (30) days prior to filing any such challenge, Licensee shall provide the University with written notice of its intent to make such challenge detailing its allegation(s) along with specific and detailed facts supporting those allegations of invalidity or unenforceability of University&#8217;s Patent Rights.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.9</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby.&nbsp;&nbsp;In the event any provision is held illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.10</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party&#8217;s right thereafter to demand compliance therewith or with any other provision.&nbsp;&nbsp;Waiver of any default shall not waive any other default.&nbsp;&nbsp;A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly authorized officer of the party making such waiver.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 5%; text-align: justify;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.11</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Licensee shall mark all Licensed Technology with applicable U.S. and foreign patent numbers in accordance with the applicable laws of the countries in which Licensed Technology is used or sold.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[remainder of page intentionally left blank]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt;">IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind the party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">UNIVERSITY OF PITTSBURGH &#8211; OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Evan Facher</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Evan Facher, Ph.D., MBA</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Director, Innovation Institute</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Vice Chancellor for Innovation and Entrepreneurship</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Date:&nbsp; January 15, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">GENPREX, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">By</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 97%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ryan M. Confer</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Name: Ryan M. Confer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Title: President and Chief Executive Officer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Date: February 17, 2025</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT A</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>THE UNIVERSITY OF PITTSBURGH AND GENPREX</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT B</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SAMPLE ROYALTY REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT C</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SAMPLE PROGRESS REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT D</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>KNOW-HOW</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><u>EXHIBIT E</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>LICENSEE CONTACT INFORMATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[***]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex_759849.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_759849.htm</title>
	<!-- Generated by ThunderDome Portal - 2/16/2025 4:25:27 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="a01.jpg" src="a01.jpg"></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Genprex Provides Update on Diabetes Gene Therapy Program</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Signs an Amended &amp; Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and Type 2 Diabetes</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><i>Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">AUSTIN, Texas &#8212; (February 18, 2025) &#8212; <u>Genprex, Inc.</u> (&#8220;Genprex&#8221; or the &#8220;Company&#8221;) (NASDAQ: <u>GNPX</u>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement of its diabetes gene therapy program, including its relationship and collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The parties have updated and consolidated the Company&#8217;s existing license agreements for technologies from Pitt into a new exclusive license agreement for multiple technologies relating to the development of a gene therapy product for both T1D and T2D. Additionally, the Company has formed a wholly-owned subsidiary, Convergen Biotech, Inc., which will focus on the Company&#8217;s diabetes program development.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;We are excited about the advances we are making with our diabetes gene therapy program, including the updated, consolidated exclusive license agreement with the University of Pittsburgh for several technology combinations,&#8221; said Ryan Confer, President and Chief Executive Officer at Genprex. &#8220;We are also pleased to have formed our wholly-owned subsidiary. In addition, we&#8217;re having ongoing discussions with various patient advocacy groups. We believe GPX-002 is a highly innovative, emerging diabetes gene therapy, and we are working to advance this program toward human clinical trials.&#8221;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Exclusive License Agreement with the University of Pittsburgh</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The new license agreement consolidates the Company&#8217;s licensed technologies from Pitt into a single updated agreement which replaces the existing license agreements with Pitt. The amended and restated agreement grants Genprex a worldwide, exclusive license to patent applications and related technologies and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy for both T1D and T2D using the genes of the Pdx1 and MafA transcription factors controlled by insulin, glucagon and MafB promoters. This license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company&#8217;s diabetes gene therapy program.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;The latest exclusive license agreement synergizes our pre-existing relationship with the University of Pittsburgh, strengthens our intellectual property portfolio for the diabetes gene therapy program and provides Genprex with valuable rights over multiple diabetes gene therapy combinations that we believe have the potential to disrupt the diabetes market,&#8221; said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. &#8220;These technologies are currently being evaluated in preclinical studies at the University of Pittsburgh. As we continue to optimize our construct, we are making strides toward clinical trials.&#8221;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The licensed technologies are based on the same general gene therapy approach under Genprex&#8217;s original licenses, whereby an adeno-associated virus vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. GPX-002 is being developed using the same construct for the treatment of both T1D and T2D. In T1D, GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body&#8217;s immune system. In a similar approach, GPX-002 for T2D, where autoimmunity is not a factor, is believed to rejuvenate and replenish exhausted beta cells.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="a01.jpg" src="a01.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Each of these technologies may have the potential to provide long-term efficacy, potentially changing the course of this disease for the millions of patients around the world with diabetes. All of the diabetes technologies licensed from Pitt by Genprex were developed in the laboratory of George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company has finalized components of the diabetes construct and is continuing with its planned preclinical studies. Genprex plans to request FDA&#8217;s guidance for the preclinical studies needed to file an Investigational New Drug (IND) application and initiate first-in-human studies and is poised for FDA Guidance on IND-enabling diabetes studies by the second half of 2025.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Formation of a Wholly-Owned Subsidiary</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition, as announced in September 2024, Genprex believes separating its diabetes program from its oncology program into a new, wholly-owned subsidiary could expedite clinical development and enable potential direct investment and strategic collaboration into its diabetes program. In connection with the intended separation of its diabetes clinical development program, Genprex has formed a wholly-owned subsidiary, Convergen Biotech, Inc. Genprex believes implementing this initial step and facilitating the separation of its diabetes program into Convergen Biotech will allow both Genprex and Convergen Biotech to enhance each program&#8217;s focus on meeting the needs of their respective markets and patients. The decision to implement this initial step of the reorganization demonstrates Genprex&#8217;s strong ongoing commitment to the Company's streamlined, focused strategies and prioritization of its ongoing research and development prioritization initiative.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>About Diabetes</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">According to the U.S. Center for Disease Control as of 2024, 38.4 million Americans, or approximately 11.6% of the U.S. population, have diabetes. Approximately 10% of this total has T1D and approximately 90-95% of this total has T2D. It is also believed that more than 97 million Americans aged 18 years or older have prediabetes. In 2021, approximately 537 million adults (20-79 years) worldwide were living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million in 2045. Approximately 7.7 million adults over the age of 20 live with T1D worldwide, and approximately 1.6 million children and adolescents under the age of 20 live with T1D worldwide. Also in 2021, diabetes caused more than 6.7 million deaths globally and diabetes resulted in approximately $966 billion dollars in health expenditures, a 316% increase over the preceding fifteen years.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>About Genprex, Inc.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex&#8217;s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex&#8217;s oncology program utilizes its systemic, non-viral Oncoprex&#174; Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company&#8217;s lead product candidate, Reqorsa&#174; Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex&#8217;s lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex&#8217;s SCLC program has received an FDA Orphan Drug Designation. Genprex&#8217;s diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body&#8217;s immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the&nbsp;Company Website, registering for&nbsp;Email Alerts&nbsp;and by following Genprex on Twitter, Facebook and LinkedIn.</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="a01.jpg" src="a01.jpg"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Cautionary Language Concerning Forward-Looking Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex&#8217;s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under &#8220;Item 1A &#8211; Risk Factors&#8221; in Genprex&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex&#8217;s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications, such as the Company&#8217;s diabetes product candidate, GPX-002; the timing and success of Genprex&#8217;s clinical trials and regulatory approvals, including, but not limited to, the Company&#8217;s diabetes clinical development program and its ongoing work with UPitt; the effect of Genprex&#8217;s product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex&#8217;s diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof, including successful implementation of the separation of its diabetes clinical development program, including the anticipated benefits of the internal reorganization, the expected timing of the reorganization and/or if it is completed as contemplated or at all; Genprex&#8217;s future growth and financial status, including Genprex&#8217;s ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex&#8217;s commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex&#8217;s intellectual property and licenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Genprex, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(877) 774-GNPX (4679)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>GNPX Investor Relations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">investors@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>GNPX Media Contact</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Kalyn Dabbs</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">media@genprex.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gnpx-20250217.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/17/2025 12:49:54 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:gnpx="http://www.gnpx.com/20250217" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gnpx.com/20250217">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20250217_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20250217_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gnpx-20250217_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.gnpx.com/20250217/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="gnpx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>gnpx-20250217_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/17/2025 12:49:54 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.gnpx.com/20250217/role/statement-document-and-entity-information" xlink:href="gnpx-20250217.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.gnpx.com/20250217/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>gnpx-20250217_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/17/2025 12:49:54 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>gnpx-20250217_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 2/17/2025 12:49:54 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.gnpx.com/20250217/role/statement-document-and-entity-information" xlink:href="gnpx-20250217.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.gnpx.com/20250217/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   /85$2
M  0    !   /80       8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $$ \P,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M-<UVX\C2M$MKE89KQ5P99BY#;(T4C+;3EF11U)$UN'\PI5X8:=)\\_A6CO\
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M.BO=V4EF9K^6SN4=/^/JYVK&%D0OM^1,,H7+%AC\M?\ @HQ_RE;^)7_8[O\
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45663100903872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">GENPREX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Feb. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">90-0772347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">3300 Bee Cave Road, #650-227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">78746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">537-7997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GNPX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001595248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #D05):EXJ[',
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MA1H#V#<YD 27Y*IU5%WI>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ Y$%26@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #D05):
M;/@4<N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #D05):F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .1!4EKZ]T\C1 0
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M2P$"% ,4    " #D05):)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #D05):99!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="gnpx20241220c_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gnpx.com/20250217/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gnpx-20250217.xsd</File>
    <File>gnpx-20250217_def.xml</File>
    <File>gnpx-20250217_lab.xml</File>
    <File>gnpx-20250217_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="gnpx20241220c_8k.htm">gnpx20241220c_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gnpx20241220c_8k.htm": {
   "nsprefix": "gnpx",
   "nsuri": "http://www.gnpx.com/20250217",
   "dts": {
    "schema": {
     "local": [
      "gnpx-20250217.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "gnpx-20250217_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "gnpx-20250217_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gnpx-20250217_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "gnpx20241220c_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.gnpx.com/20250217/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gnpx20241220c_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gnpx20241220c_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.gnpx.com/20250217/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001437749-25-004126-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-004126-xbrl.zip
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M,U5H=)]M D@E;&"R@1CT$? O-5A>C7B\-;4!;9B%2FK2'WMP>UABEB=<AA;
MA1D(987:_)RZ>*ZT("QULJ<"-4'HQR#V=1C"7C* 6:FG]INV0*&MR:E/?O-A
M-_LY$?D:( "G_5:*^0F")@ZK\33\DC1[%R57:9N#U9),??*;CY(YBC$H/08Y
M 0>!8>KYX)?,Q?;DMR=_^S#,.CXZ,]DQ8TY]D]1P?IP<?T#'3BLL6I+Y,4$\
M3FQZT1ITOH.]I^W!;P_^]F%>L)94 ?EN#WI[T+</U:(O9T:A"8*$0T.4$E#2
M;%I@H_;L-TQ^NO%GGYG\W14;+K?&.([)3G9%(7_D,LDHOP9332C;VT&6E?.P
MUY=[;%8L]8%1UM:&<3:^T*\6^?B@U!S;+H8>A3M8X-B(QSB./Y#4D6R@>TV0
M>U,5J02&6N(O&.T)[.5(E7.@35_/"530ASE+30$<?'0Y4I+=2)=H%BG,A,":
M+W0&8'3%I#"1_+LI*L LKKE%*E]74U'.KALBEZBOJRCG^  +P*R.U4PN7@?P
MD7DH.0ULC."S,-//&3^>JPC'YZ0UF<81SYS>.BZ7,P.KE6X*DTJ::@==EAX5
MO<WA],'V<M><8BR.SS$"XUS;)G/)W<EW'@V@(VYA"U=4^\SA;YB[,J4TN(;7
MM,!P_A(7L+*3%L8QS>"(V:8]F&H9:CI4<,1L?B(]/;4PE>7Y5?8<$T:I<K.2
MXU=)?RR>KN8P+M;_8%UF@8F/K#-2U64>"3ALV)<3SCTF-@J5)#'%-&8Q5IXB
M4J4#/Z:X)0D:EQZ(\@6OOW6.K6AIJA7A1YT:*&0/[XU6:XMDTK2 E86V<JJ5
M4ZMR:N/+^/JQ" M V%1_Q*2#9]6D@Z9<@BJ'O#>I8+519A(O]$KMGZ1^X1DR
M;RYPALNF:)691 #OC@C_L2<"E?H)?&CBAVXDRBM,%>50<*[!0H7QG&>9J"FF
MG<<@%>4<YRA#D*A%^)1RK)UQ2)]@DS\HD\<<4#I$6MZ/.2K0G%]\J\*%VJ4<
M=Y0B.@Y0YN!/Y7+OEL^T?&:%SVQ\M4D_SE"_ &TD<LGV!!OME>F?><.-+!=8
M>%PY;#D"]RF_/XOIFVAGP)V,<@97^C<1[G*IJV]9M2ZG.@.3RR<3[6M3Z*R0
MU9$F?Z/H1C:7X2/HJ :PV]VJTY?BD=P!Q@$<1_MVF=5NYB:=F:=1VD!@6:B?
M+FT?UJ#0S\F-)1!>8Z:87Z%N&6AX4S2WU5()6PGRQ.-7U;*FEC6MLJ9MJVU@
M3</"W)3S%&],_=E]J9#-;4T-;$A=Q8+KJ>%IHHQ5QNH5VK/)\HLI;B4#_%,2
MLHOTZ[:$H"TAV-X2@F?U$H*KSJC;'XFKP>6P>WP]ZEWVVQJ"'U:B/=O\&H*R
M>U921R\6;6#2AN3N];A(&;3%V1PKJ#$V8\O  X9J@___!"U[53,U-0,$2D=U
M?:9,ST(#L63#E )J,D:N:+#;X2<RZ,MI9I37;QT"40S;7O<7&)DJZTY>NC58
MV$61+8%EUYC^;">"I8:P.)3HZ5YU4-@J/XX07H]\HFY"\'#C+8!'L@MB6G*?
M)W&J_)RK@^TV&L2[>M>UE=)J9_/$<U0_\L@4D\,J=*I,>2/J]JB T*Q*,S9[
M7IJ 9Y?7,!'.=*79I)XU14JM@XSA85K#8]E&[.<&%P"4(VG:RC4X36VM-!=%
MCV=PL"CJ$%<!H?C9,)4)I1G2?G/?>;23@G(=)@V5@/T$Q,)[,)OQ''5,CGE>
M9FN9M'Q\E8]O6Q 16>"D$B J=Q;6$X]"7M&26>#G^&1-T 0N09] .?D%B!_^
M042)/W*8'SP>V+842/*'^T?I#.=%D!7$!0X/3*Q(I@4YCY>%1#!,$$EYE,A
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M,(:BAU1Q@PID ::X"EG>9/NG^&&B$NK;Q2CDY0(YM-@=OBEVU$-+.*"]2LD
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M]N 4][\,I&CP67!#8,J-6UAU"X=<C^\:[V[,_TIK69(@S.ZUK[R?G$S4,\X
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M[DW/3@C]?)-5DB1&MD'54OK1 8J9&CGUV(!=?T1@8JT$"^LS?$"](5U7._^
MWFQ#OJ"K%M.Y9X (E;!AFL5 GHAJ\&>2Q?RX2(;D&V@P!8'R^R52+OHHH8:9
M' Z''"\11Y5R6\QB>_1H1:PCY+BP%?7GS.K0E'+UWI34N8(,\V 63&^8IS-P
MN>]S91W^%0;8=\75._8Z'*!D^N+WO$OWF=;H?E_QT[I2?OV*MQ_M[MY1N[OW
MQ_2C;.KV_8>[>W?^'(RD_;P*52CU+OY@P.=G:5OY^OL\_&014,:?AZ5TBTES
M&R>PR.?GYO<Z6Q;J2$^GU>==**=]_4%']MD*:U3_^N3"VJ!,]/^P,K:IS#68
M[?7AR>FXV\S&,N1O6EZ,1. _J+$!JL*_M?U_4$L#!!0    ( .1!4EJ-6VY&
M:0,  &\-   1    9VYP>"TR,#(U,#(Q-RYX<V3-5]UOVS80?Q^P_X'3.TW)
M:5;8B%,4RU882+>B28&]%;1TMHE)I$92C?/?]X[ZL)7(B>R'HD^F>+_???%X
M1U^]VQ4Y^P;6*:,743*)(P8Z-9G2FT7TY8Z_O_MCN8R8\U)G,C<:%I$VT;OK
M7W^Y^HWS#Z#!2@\96SVR^VVE,[ WI@#VR5@O<\;95"1OQ32>7K)D.G\SFU^^
M89\^<D[\G<OF+MU"(1DZH=U\M[*Y6D1;[\NY$ \/#Q/:F1B[00WQA5":W$@A
M:O$NZZ$?+EIL(O[]>'L7='?@7.G_AN#);#830=I"G2]MAPPN.$@G&_--D(2B
MN6BASY3V/2;Q2KK.X\Q;[A]+<,,<% L2DXF8QPF?)M%!;C+?]ZHQ<REJ86<$
MU+#W*.@YGYI*>_LX#&Z$/8)3Z9&\J+2ON;(6R^B8ZD;:H\ NW0[#2=*#;G2Y
MZR60-B:I*4*AQ=/D;<2D]U:M*@]_&5O<P%I6.6:OTO]7,E=K!1G6>0X%:-\#
M'(B]M!OP?\L"7"E3>,5@6]"J*+'TF1ZD'2OG^A;<FE3Z< V/4NB+MSQ.6SR9
M\HMD@J8C<;(/,V%-#D+#AN[P.#]R:WLL\F)&7B2_C_3BV(T:LNZ.XL.*T^J<
MX =OVC$'7F.&;W=*],]N[L@*: F4],MSTKUO :.RW<)I<4JN7^@DH^P>4MJ/
ML^WOF].X"FO@M#@_YGZ+&Q?T(:?[.MN%@[8YRGR'#ZN^V<:PU-KXH*-U19:E
MTFM#GS3KYNW ^PQK%F;J7-J4VL7+DU>4UI1@O0)W.#.#@JV%]2*BCLO;;OLU
MEZL)SH(6\LQ OVN&=H44R&_W[K5<NKN+R&%.<ZA3_",#R6!]:B!(45K1(?QT
MT9063HT&*0Z'L#PM'J+>HX@I? 'B-/1ADO/,I%58X&.5XZ_RCYS*TQ9!?\2(
M]^7S\N597CLV7FOGU?YDZH?*F(?A=1S'^$R^:6P<+M_KC/T9S+'EWMR5>&*K
M,U\YR/[1UV&=RCRM\BZK#:E!#!'Z5?4Z_NFY/6.(WD&%G2<-0PRWE.99QN3*
M>2M3?)1Y6V'9T5'367UM$X3YJ=.S/#QBZHJ+Z!6,RK$=4''6JEV%MI2O2/K!
MFJI<1.&_R%QA">!+,!1AO8,^X5^C)>Y36%BF81<OB3+9?<!EE:W-B"[(NO_B
MYW=02P,$%     @ Y$%26IX!*SS9!   YBP  !4   !G;G!X+3(P,C4P,C$W
M7V1E9BYX;6S-6EV/XC84?:_4_Y"FSR%\S'0+6G:%F-D5ZLP.&EBUZDMEDDNP
MUK&18P;X][7#QS!+[!@&H[Q B$^NS[G^NCGBX^=52KP7X!EFM.LW:G7? QJQ
M&-.DZW\?!;U1?S#PO4P@&B/"*'1]ROS/GW[]Y>-O0? 5*' D(/8F:V\\6] 8
M^!U+P1LR+A#Q J\9-CZ$S7KSUFLT.S?MSNV--WP, O4\P?1'1WU,4 :>Y$&S
M_&?7GPDQ[X3A<KFLK2:<U!A/9(QZ*]RA_2U<M<9B_\ A^#;<-.ZA1Z&7K1S;
M:+?;8=ZZAV:X""B#-L)_'A]&T0Q2%&"JDA(I+AGN9/G-!Q8AD6>R5(*G1:A?
MP0X6J%M!HQFT&K55%OO[Q"$><4;@&:;>]O+[\^ X$YB*,,9IN,6$B!!).(\P
MXS#5$MVE3_5_JWK^_>!)L9[+>9#A=$[ #]]+*68IPC1((9T /Y-<88P+T\0I
M4+5,@DUGYS+5A+DLV9F,QJ/%!()]?V?R-41REE^8H@41[T_PVS@:NCNN/Q-5
M/25TOJI%+,UWL'I3;F4Y5;GP!<A>A!S#:)%?R.TQD-]8K.7&,&4\S?>!MQ)4
MM& 7*>=Z<B"-!JD44ZR #_+G%JNH.E&S(0$K 7*_/]B2"(N.ABS;#7D&42UA
M+V$,6/7?4A<J&:W-H '^[S[O\.[-JB!H J3KZYHW3(C:=1D_R,?UF!1/LHLS
MNMN.S.!U-,9H0J" 71GT>@SE7(2!G%J9'<LCN".F#Y @LAG#W@H7D=,@'&=N
M+,,;,G78[)C)$#AF\3V-[^3.8*!4B'.Z)I\AP9G@B(IO*"VB9H(Y93:053.?
M,YY/Y9':4OML005?]UFL)VKUE%/>7S"!;XO#LNF(Y#'$*:,Q6@UB=?I,\:::
M+J%7@G?*M1?''+)L^Z5VL(:6IP%[#8Y]>?G$QVRI/]*TR&OPRV?_$Q]R]H(W
MKU5&DAKX-9@.F2R9R+]X;ES:)K CEFK@>AR0AE=1LZLS5@8DPQFC^KU%!W'$
MZ&^.A2Q8^RQ-%W2[412=_4:<(VXC1G DRW>:/,I)S3$B!<3T($>LAAQ4%D"N
MKKS^4-4^?YI."T>S''P=EH,L6P _B:OV$5>C#=%"3K)UHSD98U%8P^L@CAB-
M.5*&WVB=3EC1U"ML=YR=^U4T0S0!39UG@CD] ^Y3X(E,QE?.EF(FY]$<T;7V
M$#"B'?'LR4D=JXG]A:"D@%EAN].<]65G')&!7&&KOT"?+0U.Q^W5]>CQR&-<
MKM^N7Y=/Y8Y0)R(L@[CK"[[83XVMV72^VS?E+#6_)+(RNT)V42:B<7$1;UV*
MLU046QT[-=<8%(,7^:JHU/]@%B_YKZK.T[6]R:B E;@G^3G3]3-(U,7)N@^L
M=Z/.8P>%G>()77%B%MGU[Y-V;(]8R&E65H[!6K'0U:J<KG)?QD+6345EG>#B
M6*B\K:A*G0UD(>F/BDJRLHXL]'VHJ+Y2R\E"VY_5UJ8SJRR4M:NMS.APV9S5
MERJ%'>DS.&,VZJI7BNC]-1L]U:M%S Z=C:;JU2$6]IZ-L.I5(F7VH(VJZE4>
MMK:BC;KJ%2&G&9$V&JM7B)BM3!M-U2M #'ZHC:#JU1WE;JK-RW15ZPT+$]9&
M7O4*#H.3:R.H>A6'A0U\X#>&/VF387]\VM]7'^H?M/+._U!+ P04    " #D
M05):&[:ZJ/H%  !$/   %0   &=N<'@M,C R-3 R,3=?;&%B+GAM;,U;[V_J
M-A3]/FG_@\>^;%+3%/JZJ57;IZKM>T*O/U"AVK2G:0J) 6N)+W),@?]^M@.4
M@!T2BIU]*8'<G'-S[HFOG:27GV=)C-XP2PG0JT;S^*2!, TA(G1XU7CM>C?=
MVW:[@5(>T"B(@>*K!H7&Y^L??[C\R?.^8HI9P'&$^G/4&TUHA-D=)!AU@/$@
M1AYJ^<W?_=9)ZPPU6Q>?SB_./J'.H^?)XV-"_[V0?_I!BI'(@Z;JZU5CQ/GX
MPO>GT^GQK,_B8V!#@7%RZB^C&XMPN3?BJP/6@\_\;.<J= MZ>JIBF^?GY[[:
MNPI-B2Y0@#;]/Q\?NN$()X%'J!0EE+FDY")5/SY &'"EY,Y30,8(^<U;AGGR
M)Z_9\DZ;Q[,T:JR$8Q#C%SQ \O/UI6UD//=EA$_Q4-;I(>CC6&2L($8,#_3'
MQ8SE#I-9G,LLFK_)+'[6H?'Y6)@C)<DXQ@W_@WEV,",0W=,#)ZR'M9!YEP>,
MV\A]&_B@V?= 7+:'S7L;\K 9B[$+'SCC+<B#9OR$#^R,3<!#9;M'FGP[Q5*Y
MQ3+F06PMPB1<P2"JV!9#]AHLGG$L6M#:*!E#N)5^NNP4*0Z/A_#F1YC(%G4J
M-SRYH3(77_ZYIYSPN>AH :%+*I7J5<.T.\LDEHT V.89%D-X\;I2I238EI;A
M%"8LS%JD8))]'%/OM=NXSKC0]XSM[TO_/9E\FC=LJ5K PAUY+"+\$$0O'//\
M.0P8) 52P2X-LE,2%$K( Q7U05PU<<9Y,R.IIJZ&B(JEW4"Q75U%AY8UEHQN
M*VP2#4JH8:7.=Q!.$DQYFPZ )6I>)D88W.8XT16]3'A%!Q1!VK;#DANMD:/O
MDAXI?K?F*"4N5%7-E6UZ03_&Y2R3"_VX711</591U+6[)*^GV2$:H:RZHR?
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MS"%!H3_)JG)I5X$=L503UQ<8&7B5%;O*5Z!!.E["9X5Q\9H@CAC]+8B$]'#
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M$%]( @W_^G0J43_JG[UPYU]02P,$%     @ Y$%26E V[OZ"&@  GYP  !0
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MI!-F*84A>J) 3&3"0R9NA)^E\AHC=S"#0C_6_?D^.&T=.(4AJRRV];_"WR8
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M<"E5LIS+--7=3/4'S'HJ[,RH:A,RC@0/P29<C#7R&KSP)T@V^&CM(+,U^F5
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M=+%=G)6Z!)B'I(912A3$-X\W4']8<S?D=&8,KR['YQCF9<;$H<6P::) ]L%
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M0QSTYU&/8)8UNE(9,!X.@,GR:Q-K) E>.^FL)*ID8=/8]G!N#,IS:,G/6:J
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M>!Z\L'L?7BAE+F=7?^=E]9=4!1M/@MH1[E>P<]P).4%0>+Y'P\WGIM9Q,R7
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M3P7)\ ^[#(-T&![\/U!+ 0(4 Q0    ( .1!4EIJV?@&A$,  ']< @ -
M          "  0    !E>%\W-3DX-#@N:'1M4$L! A0#%     @ Y$%26M&[
MC@M!%@  <EL   T              ( !KT,  &5X7S<U.3@T.2YH=&U02P$"
M% ,4    " #D05):C5MN1FD#  !O#0  $0              @ $;6@  9VYP
M>"TR,#(U,#(Q-RYX<V102P$"% ,4    " #D05):G@$K/-D$  #F+   %0
M            @ &S70  9VYP>"TR,#(U,#(Q-U]D968N>&UL4$L! A0#%
M  @ Y$%26ANVNJCZ!0  1#P  !4              ( !OV(  &=N<'@M,C R
M-3 R,3=?;&%B+GAM;%!+ 0(4 Q0    ( .1!4EH8X8@"=00  'XM   5
M          "  >QH  !G;G!X+3(P,C4P,C$W7W!R92YX;6Q02P$"% ,4
M" #D05):4#;N_H(:  "?G   %               @ &4;0  9VYP>#(P,C0Q
A,C(P8U\X:RYH=&U02P4&      < !P#  0  2(@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>gnpx20241220c_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gnpx-20250217.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001595248</identifier>
        </entity>
        <period>
            <startDate>2025-02-17</startDate>
            <endDate>2025-02-17</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-354">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-355">0001595248</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-18">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-33">2025-02-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-39">GENPREX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-51">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-56">001-38244</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-61">90-0772347</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-82">3300 Bee Cave Road, #650-227</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-87">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-92">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-102">78746</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-115">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-120">537-7997</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-365">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-366">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-367">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-368">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20258K" id="ixv-369">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20258K" id="ixv-370">GNPX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20258K" id="ixv-371">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-372">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
